Humacyte, Inc.

HUMANASDAQHealthcare● Active

$1.38

+$0.03(+2.22%)

Market Cap$231840000

P/E Ratio—

52W High$2.84

52W Low$0.547

Avg Volume7.4M

Open$1.40

Beta2.46

Overview

Humacyte, Inc. (HUMA) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

HUMA · free cash flow · updated Jun 9, 2026

Core FCF metrics

HUMA · FCF · TTM · margin & CAGR

Free cash flow was −$105.9M for FY2025 (fiscal year ending 2025-12-31), down 6.3% year-over-year

FY2025 Free Cash Flow−$105.9M▼ -6.3% YoY

Trailing 12M (TTM)−$102.4Mtrailing 4 quarters sum

FCF Margin< −999%−$105.9M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

HUMA · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$105.0M(1M)−$105.9M▼ 6.3%—

FY2024−$98.1M(2M)−$99.7M▼ 31.9%—

FY2023−$73.3M(2M)−$75.6M▼ 4.7%—

FY2022−$71.1M(1M)−$72.2M▲ +11.3%—

FY2021−$81.2M(0M)−$81.4M▼ 45.7%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

HUMA · P/FCF · FCF yield · FCF per share

Humacyte, Inc. (HUMA) reported negative free cash flow of −$0.11B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

HUMA · cash flow statement · operating / investing / financing

For FY2025, Humacyte, Inc. generated −$105.0M in operating cash flow and spent 1M in capital expenditures, yielding −$105.9M in free cash flow.

Operating Activities

−$105.0M

Cash from core business operations

2025-12-31

Investing Activities

−$0.9M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$61.5M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$105.0M) − |CapEx| (1M) = FCF (−$105.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

HUMA vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Humacyte, Inc.YOU

HUMA

−$105.9M-6.3%-5197.5%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Humacyte, Inc. (HUMA) reported free cash flow of −$105.9M for FY2025 (fiscal year ending 2025-12-31), down 6.3% year-over-year.

Humacyte, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 7 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

HUMA free cash flow · 8 questions

Humacyte, Inc. free cash flow was −$105.9M for FY2025, down 6.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$102.4M.

HUMA free cash flowHUMA FCFHUMA FCF 2025HUMA free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Humacyte, Inc. · Humacyte, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026